Bolt Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bolt Biotherapeutics, Inc. on January 3, 2025, regarding events occurring on January 2, 2025. The Company is incorporated in Delaware and its common stock trades under the symbol "BOLT".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory listing status.
Material Changes
The primary material change is the transfer of the Company's common stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. This transfer was approved by Nasdaq on January 2, 2025, and will take effect at the opening of business on January 6, 2025. The transfer was necessitated by the Company's failure to meet the $1.00 minimum bid price requirement for the Global Select Market by the December 30, 2024 deadline.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an additional 180 calendar days, until June 30, 2025, to regain compliance with the Minimum Bid Requirement.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period.
- Remedial Actions: The Company intends to monitor its stock price and evaluate options, including a potential reverse stock split, to meet the requirement.
- Delisting Risk: If the Company fails to regain compliance by June 30, 2025, Nasdaq will notify the Company of delisting. The Company may appeal such a determination, though success is not assured.
Key Facts for Investor Verification
- Verify the effective date of the listing transfer to The Nasdaq Capital Market (January 6, 2025).
- Monitor the daily closing bid price to track progress toward the $1.00 threshold for 10 consecutive days.
- Watch for announcements regarding a potential reverse stock split as a mechanism to regain compliance.
- Note the final deadline for compliance is June 30, 2025, after which delisting proceedings may commence.